AILERON THERAP. DL-,001 WKN: A2DUEV ISIN: US00887A1051 Kürzel: 015 Forum: Aktien Thema: Hauptdiskussion

Aileron Therapeutics Presents Results from Phase 1 Study in Healthy Volunteers Demonstrating ALRN-6924 Induced Cell Cycle Arrest in Bone Marrow Stem Cells and Hair Follicles at EORTC-NCI-AACR International Conference ALRN-6924 is a first-in-class MDM2/MDMX dual inhibitor that is currently in development as a novel, selective chemoprotective agent for patients with p53-mutated cancer. The findings presented at the EORTC-NCI-AACR conference, which showed that ALRN-6924 induced p53-mediated cell cycle arrest in bone marrow stem cells and hair follicles, demonstrate the potential of ALRN-6924 to prevent chemotherapy-induced neutropenia, thrombocytopenia, and anemia, as well as chemotherapy-induced alopecia. •p53-mediated cell cycle arrest results demonstrate potential of ALRN-6924 to prevent chemotherapy-induced neutropenia, thrombocytopenia, and anemia, as well as chemotherapy-induced alopecia (hair loss) •Study showed greater degree and longer duration of effect for ALRN-6924 at higher doses, supporting dose selection of 1.2 mg/kg for ongoing ALRN-6924 breast cancer trial. •3-minute IV bolus and 1-hour IV infusion demonstrated similar safety profiles, pharmacokinetics, and pharmacodynamics, providing rationale for future development of a simplified bolus administration

🤩Aileron Therapeutics kündigt mündliche Präsentation nicht-klinischer Daten an, die ALRN-6924-geschützte menschliche Haarfollikel und ihre Stammzellen vor chemotherapieinduzierten Schäden auf der Euro...

🙋‍♂️

🙋‍♀️

👀

👀

Ich sehe die 200% schon kommen

Yesssssir

👀

Hier entwickelt sich etwas

🚀

Auch einige Insider Trades in den letzten Monaten

Myelopreservation Protecting normal cells from chemotherapy Started enrollment Sept 2019 Phase 1b results 2Q-2020 MDM2-amplified cancers Final results 2Q-2020 Intellectual Property & Strategic Alliances • Composition of matter for ALRN-6924 expires 2033 (w/o ext.) • Aileron owns exclusive patent rights to ALRN-6924 worldwide http://investors.aileronrx.com/static-files/23870aaf-7ddc-41ae-8d3e-39f902f79bc5

MARKET CAP 17,239,641$ SHARES 27,810,358 Stand 30.9.2019 Cash: 24,6Mio$ Burn: 2,3Mio$ ausreichend für 10 Monate (bis Juli 2020) 290 Patente https://patentscope.wipo.int/search/en/result.jsf?_vid=P21-K4IRTU-48898 5 klinische Studien https://clinicaltrials.gov/ct2/results?cond=&term=aileron+therapeutics+&cntry=&state=&city=&dist=

Klingt nach Reverse Split, sonst war es das mit der NASDAQ: AILERON THERAPEUTICS INC : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K) 07/15/2019 | 04:33pm     Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. [...]the Company has been provided an initial period of 180 calendar days, or until January 8, 2020 (the "Compliance Date"), to regain compliance with the Bid Price Rule. If, at any time before the Compliance Date, the bid price for the Company's common stock closes at $1.00 or more per share for a minimum of 10 consecutive business days,[...] https://www.google.com/amp/s/www.marketscreener.com/amp/AILERON-THERAPEUTICS-INC-35952881/news/AILERON-THERAPEUTICS-INC-Notice-of-Delisting-or-Failure-to-Satisfy-a-Continued-Listing-Rule-or-Sta-28906969/

Hallo, ist hier noch jemand investiert? Oder warten alle mit dem investieren auf Q4 2019 bzw. Q1 2020 bis News aus der Pipeline kommen?